🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hubei Cancer Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Hubei Cancer Hospital as lead sponsor. Synced 26 Sep 2026
15Current trials
11Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hubei Cancer Hospital is the lead sponsor of 15 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Aprepitant, Cadonilimab and Dexamethasone. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1173%
  • Not yet open17%
  • Active, closed17%
  • By invitation213%

Trials by phase

  • Observational640%
  • Not applicable533%
  • Phase 2427%
01

Clinical trials sponsored by Hubei Cancer Hospital

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06020430 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy
Not applicable Recruiting 2024-02 China
DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
NCT07263347 · ClinicalTrials.gov ↗ · Breast Neoplasms, Ischemia-Reperfusion Injury, Postoperative Complications
Observational Recruiting 2025-12 China
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
NCT06080880 · ClinicalTrials.gov ↗ · Nausea With Vomiting Chemotherapy-Induced
Not applicable Recruiting 2023-12 China
SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
NCT06401005 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Recruiting 2024-11 China
A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.
NCT07250204 · ClinicalTrials.gov ↗ · Breast Cancer, Nipple Discharge
Observational Recruiting 2025-12 China
Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
NCT07264985 · ClinicalTrials.gov ↗ · Breast Cancer, Drug-Related Side Effects, Diarrhea
Observational Recruiting 2025-12 China
Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
NCT07264998 · ClinicalTrials.gov ↗ · Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Abemaciclib
Observational Recruiting 2025-12 China
SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
NCT06402435 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Recruiting 2024-11 China
Effect of Different Surgical Approaches of Granulomatous Mastitis
NCT06712524 · ClinicalTrials.gov ↗ · Breast-conserving Plastic Surgery, Granulomatous Mastitis
Not applicable Recruiting 2024-11 China
Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
NCT06037733 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Squamous Lung Cancer, Radiotherapy, Immunotherapy
Not applicable Recruiting 2024-03 China
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
NCT06032052 · ClinicalTrials.gov ↗ · Elderly Patients, Metastatic Lung Cancer
Phase 2 Recruiting 2024-02 China
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
NCT07807722 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy
Phase 2 Not yet open 2026-09 China
CNCMT:a Multi-center, Prospective, Single-arm Study
NCT06714084 · Locally Advanced Cervical Cancer, PD1, CTLA4
Not applicable By invitation 2024-10 China
Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery
NCT06258863 · ClinicalTrials.gov ↗ · Breast Neoplasm Female
Observational By invitation 2023-07 China
Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.
NCT07011329 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)
Observational Active, closed 2023-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hubei Cancer Hospital trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hubei Cancer Hospital trials

29 conditions
Breast Cancer4Radiotherapy2Immunotherapy2Breast Neoplasms2Locally Advanced Cervical Cancer1PD11CTLA41Non Small Cell Lung Cancer1Locally Advanced1Ischemia-Reperfusion Injury1Postoperative Complications1Wound Healing1Nausea With Vomiting Chemotherapy-Induced1NSCLC (Non-small Cell Lung Cancer)1EGFR1Neoadjuvant Therapy1Breast Neoplasm Female1Nipple Discharge1Drug-Related Side Effects1Diarrhea1Hormone Receptor-Positive Breast Cancer1Abemaciclib1Abemaciclib-related Diarrhea1Nasopharyngeal Carcinoma (NPC)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1511

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Breast Cancer

SponsorTrials
Fudan University48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
Second Affiliated Hospital, Zhejiang University, School of Medicine19
AstraZeneca15
Shengjing Hospital15
Pfizer12
Sichuan Baili Pharmaceutical12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences12
Hoffmann-La Roche10
Ruijin Hospital10

Sponsors with the most current trials registered for this condition.

06

Questions about Hubei Cancer Hospital trials

How many clinical trials does Hubei Cancer Hospital sponsor?

Hubei Cancer Hospital is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hubei Cancer Hospital trials recruiting?

Yes. 11 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hubei Cancer Hospital testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Aprepitant (1), Cadonilimab (1), Dexamethasone (1), Ivonescimab (1) and Ondansetron (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.